Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Active, not recruiting · NCT03241186 · Registry updated 2022-12-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | mucosal melanoma | Active, not recruiting | Phase 2 | 2022-12-09 | NCT03241186 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Hoosier Cancer Research Network | 7 |
| Robert R. McWilliams, MD | 1 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Mayo Clinic Rochester | Rochester | United States | 133 |
| Mayo Clinic- Florida | Jacksonville | United States | 3 |
| Nebraska Cancer Specialists | Omaha | United States | 40 |
| Providence Portland Medical Center | Portland | United States | 324 |
| University of Iowa Hospital and Clinics | Iowa City | United States | 30 |
| University of Minnesota | Minneapolis | United States | 1 |